Ticker

Silo Pharma (NASDAQ: SILO - Get Free Report) and Palvella Therapeutics (NASDAQ: PVLA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Risk and Volatility Silo Pharma has a

Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market,…

SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a…

Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 518,127 shares, a drop of 12.5% from the December 31st total of 592,133 shares. Approximately 4.0% of the company's shares are sold short. Based on an

Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) shares traded up 3.6% during trading on Thursday. The stock traded as high as $0.3754 and last traded at $0.3689. 45,852 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 142,715 shares. The stock had previously closed at $0.3562.